Skip to content
TrialScanner

NCT04659629

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Phase 1CompletedNGNELeadMRKCollaborator

Registry record

Lead sponsor
Neurogene Inc.
Conditions
Solid Tumor; Advanced Solid Tumor
Primary completion
Dec 15, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04659629 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04659629: NL-201 Monotherapy and in... | TrialScanner